So, from the price chart below ... came to light affecting its China division. A major UK media outlet, The Guardian, reported the following on Nov. 4th: AstraZeneca shares tumbled on Tuesday ...

Subscribe to the Daily News Brief. Nearly half of all U.S. imports—more than $1.3 trillion—come from Canada, China, and Mexico. However, analysis by Bloomberg Economics shows that the new ...

In the face of these mounting geopolitical tensions, Chinese leader Xi Jinping is doubling down, with repeated calls for China to become a “manufacturing power” and dominate global markets for ...

The shares of a group of companies associated with Xiaohongshu continued their upward momentum on Wednesday, buoyed by the Instagram-style Chinese app's ascent to the top of the download charts in ...

That came after U.S. Treasury Secretary Scott Bessent reiterated the existing long-term debt sale plan and said the Trump administration is minded to inject downward pressure on the 10-year Treasury ...

Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures ... diabetic complications are driving market expansion in countries like India, China, and Japan. Recent advancements ...

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...

AstraZeneca said it forecasts sales and earnings growth this year after fourth-quarter results beat expectations, as strength in its oncology business offset weak China sales, but warned of a ...

In November the company reported a third investigation in China involving two current and two former senior executives, relating to the import of AstraZeneca cancer drugs from Hong Kong.

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024.